Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Teams with Topin to Market OnDose to Oncologists

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has chosen Topin & Associates to help with its marketing strategy for a molecular diagnostic test to determine proper dosing for cancer drug 5-fluorouracil.

Under the terms of the deal, Topin will create a marketing strategy around the test, called OnDose, and prepare material in order to aid Myriad's sales force in selling the test to oncologists.

OnDose, which was launched in 2009, measures the level of 5-fluorouracil from a patient's blood sample. Using that information, a physician can make better dosing decisions to improve efficacy and reduce toxicity.

5-fluorouracil is used primarily in colorectal cancer and pancreatic cancer.

Topin and its medical educational partner, Advanced Clinical Concepts, also will conduct meetings in which the OnDose technology will be discussed in greater detail and compared with other methods of determining 5-fluorouracil measurement, including the body surface area method, the current standard for determining dosing of the drug.

Financial and other terms of the deal were not disclosed.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.